Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.

Drugs - 1 Apr 2018

Sanchez Jaquelyn N, Wang Ton, Cohen Mark S

Abstract excerpt

The mitogen activated protein kinase/extracellular signal-related kinase (MAPK/ERK) signaling pathway serves an integral role in growth, proliferation, differentiation, migration, and survival of all mammalian cells. Aberrant signaling of this pathway is often observed in several types of hematologic and solid malignancies. The most frequent insult to this signaling cascade, leading to its constitutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Approval
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to United States

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 29488071
DOI: 10.1007/s40265-018-0884-8
PMCID: PMC6080616

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.PMID 29488071Read ↗

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.Semantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.Semantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.